28155918|t|Surface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action
28155918|a|The alarming increase of pathogenic bacteria that are resistant to multiple antibiotics is now recognized as a major health issue fuelling demand for new drugs. Bacterial resistance is often caused by molecular changes at the bacterial surface, which alter the nature of specific drug-target interactions. Here, we identify a novel mechanism by which drug-target interactions in resistant bacteria can be enhanced. We examined the surface forces generated by four antibiotics; vancomycin, ristomycin, chloroeremomycin and oritavancin against drug-susceptible and drug-resistant targets on a cantilever and demonstrated significant differences in mechanical response when drug-resistant targets are challenged with different antibiotics although no significant differences were observed when using susceptible targets. Remarkably, the binding affinity for oritavancin against drug-resistant targets (70 nM) was found to be 11,000 times stronger than for vancomycin (800 Î¼M), a powerful antibiotic used as the last resort treatment for streptococcal and staphylococcal bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Using an exactly solvable model, which takes into account the solvent and membrane effects, we demonstrate that drug-target interactions are strengthened by pronounced polyvalent interactions catalyzed by the surface itself. These findings further enhance our understanding of antibiotic mode of action and will enable development of more effective therapies.
28155918	0	7	Surface	T082	C0205148
28155918	29	50	interactions of drugs	T044	C0687133
28155918	51	58	enhance	T052	C2349975
28155918	59	76	mechanical forces	T067	C0563538
28155918	81	91	antibiotic	T195	C0003232
28155918	92	98	action	T052	C3266814
28155918	103	120	alarming increase	T169	C0442805
28155918	124	143	pathogenic bacteria	T001	C0450254
28155918	153	186	resistant to multiple antibiotics	T046	C0860044
28155918	210	228	major health issue	T033	C4060919
28155918	238	244	demand	T061	C0441516
28155918	253	258	drugs	T121	C1254351
28155918	260	280	Bacterial resistance	T046	C0151521
28155918	300	317	molecular changes	T033	C0262496
28155918	325	342	bacterial surface	T034	C0201029
28155918	379	403	drug-target interactions	T044	C0687133
28155918	431	440	mechanism	T169	C0441712
28155918	450	474	drug-target interactions	T044	C0687133
28155918	478	496	resistant bacteria	T007	C1444090
28155918	504	512	enhanced	T052	C2349975
28155918	530	537	surface	T082	C0205148
28155918	530	537	surface	T082	C0205148
28155918	538	544	forces	T067	C0441722
28155918	563	574	antibiotics	T195	C0003232
28155918	576	586	vancomycin	T116,T195	C0042313
28155918	588	598	ristomycin	T116,T195	C0917879
28155918	600	616	chloroeremomycin	T116,T121	C0674648
28155918	621	632	oritavancin	T116,T121	C1144403
28155918	641	657	drug-susceptible	T169	C0231204
28155918	662	684	drug-resistant targets	T007	C4076168
28155918	718	729	significant	T078	C0750502
28155918	745	755	mechanical	T169	C0443254
28155918	756	764	response	T032	C0871261
28155918	770	792	drug-resistant targets	T007	C4076168
28155918	823	834	antibiotics	T195	C0003232
28155918	876	884	observed	T169	C1441672
28155918	896	915	susceptible targets	T169	C0231204
28155918	933	949	binding affinity	T039	C0678749
28155918	954	965	oritavancin	T116,T121	C1144403
28155918	974	996	drug-resistant targets	T007	C4076168
28155918	1052	1062	vancomycin	T116,T195	C0042313
28155918	1084	1094	antibiotic	T195	C0003232
28155918	1112	1128	resort treatment	T061	C0087111
28155918	1133	1146	streptococcal	T007	C0038402
28155918	1151	1174	staphylococcal bacteria	T007	C0038170
28155918	1185	1228	methicillin-resistant Staphylococcus aureus	T007	C1265292
28155918	1230	1234	MRSA	T007	C1265292
28155918	1246	1268	exactly solvable model	T170	C0282574
28155918	1299	1306	solvent	T130	C0037638
28155918	1311	1319	membrane	T026	C0596901
28155918	1320	1327	effects	T080	C1280500
28155918	1349	1373	drug-target interactions	T044	C0687133
28155918	1394	1428	pronounced polyvalent interactions	T044	C0687133
28155918	1429	1438	catalyzed	T070	C0007382
28155918	1446	1453	surface	T082	C0205148
28155918	1485	1492	enhance	T052	C2349975
28155918	1497	1510	understanding	T041	C0162340
28155918	1514	1539	antibiotic mode of action	T169	C1524059
28155918	1556	1567	development	T169	C1527148
28155918	1586	1595	therapies	T061	C0087111